Karo Pharma, an EQT VIII portfolio company, has announced the acquisition of the remaining European rights to the Pevaryl brand portfolio from Cilag GmbH International, an affiliate of Johsnon & Johnson

The acquisition consolidates the full ownership of the Peravyl brand portfolio with Karo Pharma. The portfolio generated net sales of approximately €20M in 2019. 

Karo Pharma already commercializes and owns Gyno-Pevaryl , Epi – Pevaryl and Pevaryl in certain European markets. 

The brand portfolio is available in more than 20 European countries with 30M in net sales. This acquisition adds scale and scope in new regions such as Italy as well as focus categories of intimate care and foot care. 

Source: Karo Pharma

Share this story

Menu
Do NOT follow this link or you will be banned from the site!
close-link
close-link

close-link
close-link
close-link